Kadmon — Technical Presentation (December 2020)
18 slides from Kadmon's technical presentation, Dec 7, 2020
Slide 1: Follow-up Analysis of KD025-213 (the ROCKstar Study)
American Society of Hematology Helping hematologists conquer blood diseases worldwide 2 - ™ Follow-up Analysis of KD025-213 (the ROCKstar Study): A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Patients With c@VHD Corey Cutler,’ Stephanie J. Lee,2 Zachariah D
Slide 2: The Pathophysiology of cGVHD
The Pathophysiology of cGVHD Chronic GVHD is driven by both immune and fibrotic processes * Chronic GVHD involves both T cells and B cells — Overproduction of pro-inflammatory IL-21 and IL-17 cytokines — Overactivation of Tfh cells and B cells, leading to the overproduction of antibodies — Deficienc
Slide 3: ROCK2 Plays a Key Role in Immune Diseases
ROCK2 Plays a Key Role in Immune Diseases Autoaggressive inflammatory response Restored immune homeostasis ROCK2 inhibition rebalances immune response to treat immune dysfunction + ROCKs are serine-threonine kinases + Two isoforms: ROCK1 and ROCK2 coe etre + ROCK2 inhibition rebalances the immune sy
Slide 4: ROCK Is an Intracellular Integrator of Profibrotic Signals
ROCK Is an Intracellular Integrator of Profibrotic Signals Matrix stiffness at Stress fiber ROCK regulates multiple profibrotic processes, including myofibroblast activation + ROCK is downstream of major profibrotic mediators + ROCK mediates stress fiber formation * ROCK regulates transcription of p
Slide 5: Rationale for Belumosudil (KD025) in cGVHD
Rationale for Belumosudil (KD025) in cGVHD ¢ Belumosudil, an investigational drug, is an oral selective ROCK2 inhibitor’ — More than 550 individuals have received belumosudil in ongoing and completed studies * Targets both the immune and the fibrotic pathophysiology of cGVHD' * Preclinical data in s
Slide 6: Study Design and End Points
The ROCKstar Study: Study Design and End Points Eligibility criteria + Aged 212 years + Underwent an HCT + Had active cGVHD OPEN LABEL PRIMARY END POINT oes ARM A: Belumosudil 200 mg QD ORR, per 2014 NIH * 2 to 5 prior lines of cGVHD Consensus systemic therapy Criteria for c6VHD + Systemic therapy f
Slide 7: Fully Enrolled in <10 Months
The ROCKstar Study: Fully Enrolled in <10 Months * 28US sites ¢ Enrollment period: October 2018 to August 2019 eS American Society of Hematology
Slide 8: Diverse Patient Population
The ROCKstar Study: Diverse Patient Population Select Demographics and Baseline Characteristics Median age, y (range) 57 (21-77) Male,% 64 50 " Median prior lines of therapy, n 5 4 Median time from cGVHD diagnosis to enrollment, mo 25 30 NIH moderate cGVHD, n (%) 18 @7) 23 (35) "NIH severe cGVHD,*n
Slide 9: Safety and Tolerability
The ROCKstar Study: Safety and Tolerability Belumosudil Belumosudil Commonly reported AEs, n (%) 200mgQD 200 mg BID mooy 08) kee) : + AEs were overall consistent with those expected in patients with All grades in 220% of patients cGVHD receiving corticosteroids and other immunosuppressants Fatigue 3
Slide 10: Primary End Point Met
The ROCKstar Study: Primary End Point Met Belumosudil achieved clinically meaningful and statistically significant ORRs in both arms 100 90 73% 77% 80 (95% Cl, 60%-83%) __ (95% Cl, 65%-87%)? 70 = 60 a 50 & 40 Belumosudil 200 mg QD _Belumosudil 200 mg BID (n=66) (n=66) CR, complete response. *P<.0001
Slide 11: Responses Observed Across All Key Subgroups
The ROCKstar Study: Responses Observed Across All Key Subgroups Group name ORR, % (95% Clr) Group name All patients (N=132) 75 (67-82) he Number of organs involved at baseline Belumosudil 200 mg QD (n=66) 73 (60-83) be 24 (n=68) Belumosudil 200 mg BID (n=66) 77 (65-87) oe <4 (n=64) ‘Severe GVHD at s
Slide 12: Responses Observed Across All Organ Systems
The ROCKstar Study: Responses Observed Across All Organ Systems CRs observed in all organs Responder population (n=99) 100 1 90 - 88 83 =CR PR 80 5 13 75 70 70 | = 60 64 w 50 49 47 46 6 0 75 28 70 32 30 | 18 20 | 10 5 al 17 18 0 Joints/Fascia Lower GI Upper GI Mouth Esophagus Eyes Skin Liver Lungs (
Slide 13: DOR
The ROCKstar Study: DOR Kaplan-Meier plot of DOR 1.0 08 2 os a s ¢ 5 S04 = —— Og — Belumosudil 200 mg QD — Belumosudil 200 mg BID — Overall 00 0 4 8 12 16 2 24 28 32 36 40 44 48 52 56 60 64 G8 72 76 80 84 88 Weeks Number at risk elumosudil200mgQ0 4 3 ' Belumosuall 200mg BID $1 48 44 41 35 30 28 21 1
Slide 14: FFS
The ROCKstar Study: FFS Kaplan-Meier plot of FFS ‘Treatment: overall 104 + Censored 08-4 Zoe a 2 04 é An FFS rate of 02 0, 58% was 0.0 . . r r z z r : ’ r y maintained o 3 6 9 12 15 18 20 24 Months: Number at risk 132 112 97 86 62 27 7 3 1 at 12 months. rs 100 aur 762 8 ors 26 as ws aes Newtteatment
Slide 15: OS
The ROCKstar Study: OS Kaplan-Meier plot of OS 1.0 -—w, os 08 3 The OS rate 8 04 at 24 months was 89% 02 (95% Cl, 82%-93%). — Belumosudit 200 mg a0 = Betumosudt 200 mg BID — Overall 0.0 0 é R 8 ’ 24 Number at ik Months etumosual!200"mg10 68 @ Hy ° Overall 132 t~ a“ n 8 *: American Society of Hematol
Slide 16: Additional End Points
The ROCKstar Study: Additional End Points ¢ Overall, 64% of patients were able to reduce their CS dose, and 21% discontinued CS therapy — The mean CS dose was reduced by 44%; 52% in responders and 17% in nonresponders ¢ Overall, 45% of patients were able to reduce their CNI dose, and 22% discontinue
Slide 17: Conclusions
The ROCKstar Study: Conclusions Belumosudil was well tolerated and achieved clinically meaningful outcomes * ORR of >70% across QD and BID treatment arms — Responses observed across all key subgroups — Responses observed in all affected organ systems, including in organs with fibrotic disease ¢ Addi
Slide 18: Acknowledgements
Acknowledgements Study patients and their caregivers All ROCKstar study investigators and all site staff, nurses and study coordinators The KD025-213 Steering Committee — Corey Cutler, MD (chair), Dana-Farber Cancer Institute, Boston, MA — Steven Z. Pavletic, MD (co-chair), National Cancer Institute
Kadmon Holdings — Technical Presentation (December 2020) on 6ix